QQ客服 官方微博 反馈留言

	Biomarker analysis from a phase 1 study of palbociclib (PAL) plus letrozole (L) as first-line treatment for ER+/HER2-advanced breast cancer (ABC) in Chinese women
	Xu, Binghe; Zhang, Qingyuan; Li, Huiping; Sun, Wan; Li, Wei; Wang, Shusen; Liao, Ning; Shen, Peng; Shao, Bin; Zhao, Wenhui
	2018
卷号	78期号:13
ISSN号	0008-5472
DOI	10.1158/1538-7445.AM2018-CT048
URL标识	查看原文
收录类别	SCIE
内容类型	期刊论文
URI标识	http://www.corc.org.cn/handle/1471x/6347118
专题	中国医学科学院 北京协和医学院
推荐引用方式 GB/T 7714	Xu, Binghe,Zhang, Qingyuan,Li, Huiping,et al. Biomarker analysis from a phase 1 study of palbociclib (PAL) plus letrozole (L) as first-line treatment for ER+/HER2-advanced breast cancer (ABC) in Chinese women[J],2018,78(13).
APA	Xu, Binghe.,Zhang, Qingyuan.,Li, Huiping.,Sun, Wan.,Li, Wei.,...&Wang, Diane D..(2018).Biomarker analysis from a phase 1 study of palbociclib (PAL) plus letrozole (L) as first-line treatment for ER+/HER2-advanced breast cancer (ABC) in Chinese women.,78(13).
MLA	Xu, Binghe,et al."Biomarker analysis from a phase 1 study of palbociclib (PAL) plus letrozole (L) as first-line treatment for ER+/HER2-advanced breast cancer (ABC) in Chinese women".78.13(2018).

个性服务

查看访问统计

相关权益政策

暂无数据

收藏/分享

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。